Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 262

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 262
---
|                               |     | 2024 |        |   |     | 2023 |        |   |
| Federal                       |     |      |  21.00 | % |     |      |  21.00 | % |
| State                         |     |      |   2.07 | % |     |      |   2.55 | % |
| Nondeductible expenses        |     |      |  -2.33 | % |     |      |  -3.85 | % |
| Change in valuation allowance |     |      | -20.74 | % |     |      | -19.70 | % |
| Effective tax rate            |     |      |      - |   |     |      |      - |   |

| F-20 |

JUPITER NEUROSCIENCES, INC.

NOTES TO FINANCIAL STATEMENTS

December 31, 2024 and 2023

Note 7 – Income Taxes, continued

A summary of the Company’s deferred tax assets is as follows:

Schedule of Deferred Tax Assets

|                                          |     |   |       2024 |   |     |   |       2023 |   |
|:-----------------------------------------|:----|:--|-----------:|:--|:----|:--|-----------:|:--|
| U.S Federal and State net operating loss |     | $ |  3,083,545 |   |     | $ |  2,429,544 |   |
| Stock based compensation                 |     |   |  1,272,925 |   |     |   |  1,031,860 |   |
| Accrued salaries                         |     |   |    382,288 |   |     |   |    395,899 |   |
| Orphan drug credit                       |     |   |  1,060,118 |   |     |   |    924,171 |   |
| Derivative liability                     |     |   |          - |   |     |   |    370,572 |   |
| Other                                    |     |   |    260,481 |   |     |   |    392,486 |   |
| Total net deferred tax assets            |     |   |  6,059,357 |   |     |   |  5,544,532 |   |
| Valuation